View all veterinary jobs
Alstoe Ltd has launched Tempora, a chewable, flavoured, spironolactone tablet for dogs, indicated for the treatment of congestive heart failure (CHF) arising from mitral valve disease.
Alstoe says Tempora's flavouring technology, tablet shape and two and four way break tablets facilitate ease of use and should improve compliance. The company also highlights the affordability of the new product, which can be used alone or in conjunction with standard therapies.
According to Alstoe, it is estimated that in 75% of dogs with CHF, degenerative mitral valve disease is the underlying cause. The company says spironolactone shows clear benefits in treating mxyomatous mitral valve disease (MMVD) in dogs: acting as an aldosterone receptor antagonist it counteracts the negative consequences of aldosterone production such as myocardial fibrosis and myocardial and vascular remodelling.
To support the new product, Alstoe has designed a Sleep Respiratory Rate (SRR) chart to assist veterinary professionals with ongoing monitoring of their canine patients condition and response to treatment. The chart is available as a printable download or in pads. The company is also offering lunchtime practice seminars.
Tempora is available as 10mg, 50mg and 100mg tablets.
For further information, contact Alstoe Animal Health on 01347 878606, or via e-mail: adelaideellerington@alstoe.co.uk, or visit www.alstoe.co.uk